ARTICLE | Company News
RegeneRx, National Institutes of Health deal
February 12, 2001 8:00 AM UTC
RGRX received exclusive worldwide rights to the NIH's angiogenesis-stimulating synthetic Thymosin beta 4 for use in wound healing. RGRX expects to begin Phase I testing of the compound later this yea...